Search This Blog

Friday, June 11, 2021

UK To Extend Lockdown One Month As Indian Variant Spooks Officials Into Vaccine Scramble

 UK Prime Minister Boris Johnson is set to delay the country's "freedom day" from lockdowns by just under one month - from June 21 to July 19 - after the 'Delta variant' COVID-19 strain from India exploded 240% in one week, as was first reported by The Sun, and later confirmed by the Financial Times via comments by England's Chief Medical Officer, Chris Whitley, who requested the delay.

Under plans drawn up to be announced on Monday, a two-week review will be included meaning Covid restrictions could be dropped on July 5 if hospitalisations stay down.

But multiple sources told the Sun the chances of lifting restrictions as planned on June 21 were close to zero - in a massive blow to Wembley hosting of the Euros.

Group games will have a 25 per cent stadium cap - 22,500 fans - with that hopefully rising to around 45,000 for the Semis and the July 11 Final.

Freedom loving Brits are livid at the prospect...

Downing Street was reportedly spooked after cases of the Indian variant began to spike last week - as Public Health England says infections have risen from 12,431 last week to 42,323 - a jump of 240%. The new variant is 2/3 more likely to spread via close contacts, as cases have more than tripled in the last 11 days. Doubling rates for the Delta variant were as high as 4.5 days in some parts of England, with 96% of new cases attributed to the new strain.

According to the Financial Times"Whitty told the prime minister a four-week delay was vital to avoid a situation in which restrictions are lifted prematurely, only to have to be restored later," news that comes as the UK records its highest weekly rate of COVID-19 cases since early March, with 45,895 new infections reported in the past week.

That said, according to Downing street, "no decisions have been taken" regarding lifting restrictions on June 21, and Johnson may relax guidance on the size of weddings even if he maintains other restrictions into July.

Vaccine push

"It is now critical we double jab everyone as quickly as possible," said one UK official, per the Times, while one Cabinet Office insider said "A delay [to lifting the final restrictions] is the only sensible course of action. It’s our working assumption. The latest modelling is dire and it would be suicide to go ahead with a full easing."

And as The Sun notes:

Just six per cent of all Delta variant infections were in people who had both jabs.

More than half of the 42 deaths due to the mutation were in unvaccinated Brits.

Dr Jenny Harries, Chief Executive of the UK Health Security Agency, said: “With numbers of Delta variant cases on the rise across the country, vaccination is our best defence.

If you are eligible, we urge you to come forward and be vaccinated.

Remember that two doses provide significantly more protection than a single dose."

According to the report, the delay will be used to determine if the vaccine rollout coincides with a reduction - or at least no surge - in hospitalizations, as millions of people receive both jabs.

Of course, this will make lockdown proponents giddy as school girls.

https://www.zerohedge.com/covid-19/uk-extend-lockdown-one-month-indian-variant-spooks-country-vaccine-scramble 

 

EHR market share 2021: 10 things to know about major players Epic, Cerner, Meditech & Allscripts

 While the COVID-19 pandemic has significantly affected hospital operations, EHR purchasing activity increased in 2020 largely by big organizations and standalone community hospitals, according to a recent KLAS Research report. 

For its "U.S. Hospital Market Share 2021" report, KLAS examined EHR purchasing activity and contracts across the country from Jan. 1 to Dec. 31, 2020. This includes EHR market share data for acute care specialty hospitals and other specialty hospitals. 

Here are 10 things to know about the EHR market and top vendors:  

1. The pandemic's effect on EHR contracting varied throughout 2020, with 77 hospitals reporting an impact on their contract during the first quarter of the year. 

2. This number shrunk to 30 hospitals in the second quarter and gradually increased to 41 hospitals by quarter three. By the fourth quarter, 71 hospitals reported that COVID-19 affected EHR contracting. 

3. Epic now maintains nearly one-third (31 percent) of the EHR market share, followed by Cerner at 25 percent, Meditech at 16 percent and Allscripts at 5 percent. 

4. Of the major vendors, Epic was the only EHR company to report a positive net change in acute hospital market share, up 101. Cerner, Meditech and Allscripts all dropped by 19, nine and one, respectively. 

5. Allscripts and Epic both added hospital beds in 2020, with net changes of +13 and +19,247, respectively. Cerner lost 10,480 hospital beds and Meditech lost 3,458 beds for the year. 

6. Cerner reported 23 inpatient specialty hospital wins for 2020, followed by Meditech with seven and Epic with five. 

7. Meditech was the only major vendor to record acute care hospital migrations during the year, with 14 wins total. 

8. Breaking down the types of acute care hospital wins among the vendors, KLAS defined three categories: competitive wins, customer migrations and merger and acquisition standardization. Epic saw the most competitive wins with 83, followed by Cerner with 24 and Meditech with 11. 

9. For customer migration wins, Meditech outscored the other vendors with 14 total; for M&A standardization wins, Epic led the pack with 21, followed by Cerner with 16, Meditech with five and Allscripts with four. 

10. Cerner secured the most contracts with small standalone hospitals, with 19 total wins, followed by Meditech with nine and Epic with four.

https://www.beckershospitalreview.com/ehrs/ehr-market-share-2021-10-things-to-know-about-major-players-epic-cerner-meditech-allscripts.html

 

  • Curis Inc (NASDAQ: CRIShas announced updated data from its ongoing Phase 1/2 study of CA-4948 in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS).

  • Key findings were presented at the European Hematology Association 2021 Virtual Congress and included data from 22 patients (11 with high-risk MDS, 11 with AML).

  • The primary objective was to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) for CA-4948.

  • The company has found 300mg twice daily as the recommended Phase 2 dose in AML and high-risk MDS after observing no dose-limiting toxicities (DLT).

  • Out of 17 evaluable patients at the April 30 cutoff, five objective responses were observed, including one complete response (CR), one complete remission with incomplete hematologic recovery (Cri) & negative minimal residual disease, one partial response (PR), and two marrow CRs.

  • As reported earlier, 4 DLTs were observed in patients dosed higher than the Recommended Phase 2 Dose.

  • In the 400mg group, two patients experienced severe rhabdomyolysis.

  • In the 500mg arm, one patient experienced severe rhabdomyolysis and one syncope.

Orphazyme addresses recent trading activity

 Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases, today announced that American Depositary Shares (ADSs) representing its ordinary shares on Nasdaq US have since June 10, 2021 experienced extreme volatility in price and trading volume. The company is not aware of any material change in its clinical development programs, financial condition or results of operations that would explain such price volatility or trading volume that has occurred since June 10, 2021. Investors who purchase the company’s ADS or shares may lose a significant portion of their investments if the price of such securities subsequently declines.

Orphazyme’s applications for arimoclomol (to be branded MIPLYFFATM)1 for Niemann-Pick disease type C (NPC) are under priority review with the U.S. Food and Drug Administration, with an expected PDUFA action date of June 17 2021, as well as with the European Medicines Agency, with an opinion from the Committee for Medicinal Products for Human Use (CHMP) expected later this year.

https://www.globenewswire.com/news-release/2021/06/11/2245674/0/en/Orphazyme-addresses-recent-trading-activity.html

Moderna Says It Doesn’t See Signs That Shot Causes Heart Issue

 Moderna Inc. said that scientific evidence it has reviewed doesn’t suggest that its Covid-19 vaccine was the cause of a heart condition in some people who received it.

The drugmaker said in a statement Friday that after reviewing the available safety data on its shot for cases of myocarditis and pericarditis, it “has not established a causal association with its vaccine.”

U.S. public health advisers plan to meet later this month to discuss a potential link between Covid-19 shots that use messenger RNA technology, which include Moderna’s vaccine and one made by Pfizer Inc. and BioNTech SE, and heart inflammation after hundreds of vaccinated people experienced myocarditis.

Moderna said it “will continue to closely monitor these reports and is actively working with public health and regulatory authorities to further assess this issue.”

The Centers for Disease Control and Prevention has identified a total of 216 cases of heart inflammation after the first dose of an mRNA shot, and another 573 cases after the second dose. The median age of people with myocarditis or pericarditis following the first dose was 30, and 24 in the second-dose cases. There were 475 cases among people under 30.

Moderna’s vaccine is now authorized for adults 18 and up, but it is under FDA review for children ages 12 to 17.

Most patients have responded well to treatment and rest, according to the CDC, and more than 8 in 10 have had full relief from their symptoms. The agency is further examining the cases by age.

About 130 million Americans have received the full two-dose regimen of one of the two authorized mRNA vaccines.

https://www.bloomberg.com/news/articles/2021-06-11/moderna-says-it-doesn-t-see-signs-that-shot-causes-heart-issue

Vaxart started at Overweight by Piper Sandler

 Target $18

https://finviz.com/quote.ashx?t=VXRT&ty=c&ta=1&p=d

Why Callaway Golf and Apollo Medical Stocks Moved Today

 Online delivery service Grubhub (NYSE:GRUB) has been purchased by Netherlands-based Just Eat Takeaway.com (OTC:TKAY.Y) and will be leaving U.S. stock indexes as a result. The resulting shuffle will affect the placement of Callaway Golf (NYSE:ELY) as well as Apollo Medical Holdings (NASDAQ:AMEH), and the stocks are moving today because of it. At 11:45 a.m. EDT, Callaway Golf shares were down about 3%, but ApolloMed stock had jumped almost 17%. 

On June 15, Callaway Golf will replace Grubhub in the S&P MidCap 400 index, while healthcare management company ApolloMed will join the S&P SmallCap 600.


ApolloMed provides its solutions to physicians, health plans, hospitals, and other health providers using its technology and healthcare model. The company aims to maximize efficiency and quality of care while reducing unnecessary hospital admissions, re-admissions, and emergency room visits. The California-based $2 billion company has been growing, having recently acquired Sun Clinical Labs to integrate its value-based care delivery platform.  

The larger Callaway Golf, which has a market cap of about $6.5 billion, has also been expanding recently. It completed its merger with golf entertainment and experience company Topgolf in March 2021. In its first-quarter 2021 financial update, Callaway said Topgolf has been exceeding expectations because its business recovered from pandemic impacts sooner than anticipated. Callaway raised guidance for investors in its May release, saying it now expects 2021 results from the legacy Callaway business and the Topgolf business will each exceed 2019 levels. The company previously didn't expect to reach that level by the end of 2021. 

https://www.fool.com/investing/2021/06/11/heres-why-callaway-golf-and-apollo-medical-stocks/